# Shanghai Chenggeng Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-chenggeng-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $28M
- Latest round: Series A (Dec 31, 2025)
- Investors on record: 2

## About

Based in Shanghai, China and founded in 2022, Shanghai Chenggeng Biotechnology Co., Ltd., is a provider of comprehensive precision microbiome transplantation solutions, primarily engaged in the development of the Precision Microbiome Transplantation Treatment Platform (PMTT). Based in Shanghai, China and founded in 2022, Shanghai Chenggeng Biotechnology Co., Ltd., is a provider of comprehensive precision microbiome transplantation solutions, primarily engaged in the development of the Precision Microbiome Transplantation Treatment Platform (PMTT). In December 2025, Shanghai Chenggeng Biotechnology Co., Ltd. raised over CNY 100 million in Series A funding from new investor Grand Flight Investment.

It specializes in human microbiome transplantation, with business areas spanning microbiome health, microbiome diagnostics, microbiome therapy, microbiome drugs, and microbiome medical big data mining.
The company generates revenue by providing comprehensive solutions for precision microbiome transplantation.

## Funding rounds

- Series A, Dec 31, 2025, $14M — Grand Flight Investment
- Angel, Jun 26, 2025, $14M — Jinyuan Kuntong Equity Investment Management

## Investors

- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Angel
- Grand Flight Investment (https://capitalatlas.ai/funds/grand-flight-investment) — Series A